12/1/2020 7:09:56 AM
TG Therapeutics Initiates Rolling Submission Of BLA For Ublituximab In Combination With Umbralisib
10/21/2020 7:41:14 AM
TG Therapeutics: Fast Track Designation Granted By FDA To Ublituximab In Combination With Umbralisib
8/13/2020 7:17:00 AM
TG Therapeutics Announces FDA Acceptance Of NDA For Umbralisib; Sets PDUFA Goal Date Of June 15, 2021
6/17/2020 7:13:07 AM
TG Therapeutics Completes Rolling Submission Of NDA For Umbralisib
5/29/2020 8:17:35 AM
TG Therapeutics Announces Final Results Of GENUINE Phase 3 Study Evaluating Ublituximab Plus Ibrutinib
5/15/2020 12:43:28 AM
TG Therapeutics Prices Underwritten Public Offering Of 8.5 Mln Shares At $18/Shr
3/3/2020 7:14:52 AM
TG Therapeutics Q4 Net Loss $39.6 Mln Vs Loss $53.9 Mln Last Year
1/16/2020 7:36:44 AM
TG Therapeutics Initiates Rolling Submission Of NDA To FDA For Umbralisib
9/12/2019 7:35:41 AM
TG Therapeutics Presents Data For Ublituximab At The 35th Annual Congress Of ECTRIMS
6/17/2019 7:50:18 AM
TG Therapeutics Announces Presentation Of Preclinical Data For TG-1801
6/17/2019 7:38:39 AM
TG Therapeutics Presents Preclinical Data For TG-1801 At EHA
6/11/2019 7:59:55 AM
TG Therapeutics Confirms Registration Path For Umbralisib Following FDA Meeting